This legislation establishes the National Biotechnology Initiative (NBI) to enhance national security, economic productivity, and competitiveness by coordinating and advancing Federal activities related to biotechnology. The President, acting through the Executive Office of the President, is mandated to implement this initiative, involving a broad array of participating agencies including the Departments of Agriculture, Defense, Energy, Health and Human Services, and the National Science Foundation, among others. A central component of the NBI is the creation of the National Biotechnology Coordination Office (NBCO) within the Executive Office of the President, led by a Director who serves as the principal advisor to the President on biotechnology. This office is responsible for planning, management, and coordination, including advising the Office of Management and Budget on agency spending and coordinating Federal regulation of biotechnology products. The bill also designates an Interagency Committee , comprising Assistant Secretary-level members from participating agencies, to oversee the Initiative's activities. This committee, co-chaired by the NBCO Director and two elected members, ensures that each agency supports the Initiative through relevant activities and facilitates interagency communication and collaboration. Key functions of the Initiative, to be carried out by both the NBCO and participating agencies, span several critical areas. These include developing a national strategy, assessing national security implications of emerging biotechnology, and providing sustained support for biotechnology research and development. The Initiative also prioritizes the management of biological data and databases as a strategic national resource, focusing on standardization, security, and interoperability. Efforts will be made to streamline regulations for biotechnology products, easing regulatory burdens and establishing clear pathways, with the Office of Management and Budget stepping in if interagency agreement cannot be reached. Furthermore, the NBI addresses biosafety and biosecurity issues, developing strategies to mitigate potential threats. It emphasizes workforce development by coordinating training programs and educational initiatives to build a robust domestic biotechnology workforce across public and private sectors. The bill mandates the development of a coordinated Federal website to provide clear, accessible information on biotechnology for policymakers, innovators, and the public, promoting bioliteracy . It also focuses on strengthening international partnerships through regulatory and commercial diplomacy, talent exchanges, and harmonization of export controls. To ensure accountability and transparency, the NBCO and Interagency Committee are required to submit annual reports and a comprehensive national strategy for biotechnology every five years. The Comptroller General will conduct periodic reviews to assess the Initiative's efficacy and recommend improvements. Funding for the NBCO's administrative support is authorized, starting with $22 million in fiscal year 2026 and totaling $132 million through fiscal year 2030. The Office is designed to wind down its direct operational activities after 20 years, transitioning to an executive secretariat role, with its functions and resources transferred to the Interagency Committee or other Federal entities. This ensures a long-term, coordinated approach to advancing biotechnology for the benefit of the United States.